| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA 300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Abatacept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abemaciclib |
08.01.05 |
Formulary
|
NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration resistant prostate cancer |
| Abiraterone |
08.03.04.02 |
Formulary
|
NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Adalimumab |
01.05.03 |
Formulary
|
NICE TA187: Crohn’s disease - infliximab and adalimumab |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Adalimumab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Adalimumab injection |
13.05.03 |
Formulary
|
NICE TA146 Adalimumab for the treatment of adults with psoriasis |
| Adalimumab injection |
13.05.03 |
Formulary
|
NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Adalimumab injection |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab injection |
11.04.02 |
Formulary
|
NICE TA 460 Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a |
| Adefovir Dipivoxil |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Adrenaline (epinephrine) injection |
03.04.03 |
Formulary
|
NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment |
| Afatinib |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 346 Aflibercept for treating diabetic macular oedema |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 305 Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 294 Aflibercept solution for injection for treating wet age‑related macular degeneration |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA 486 Aflibercept for treating choroidal neovascularisation |
| Aflibercept |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Alemtuzumab |
08.02.03 |
Non Formulary
|
NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis |
| Alirocumab |
02.12 |
Formulary
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin |
13.05.01 |
Formulary
|
NICE TA 177 Alitretinoin for the treatment of severe chronic hand eczema |
| Alteplase |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Anastrozole |
08.03.04.01 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Anastrozole |
08.03.04.01 |
Formulary
|
NICE CG 81 Advanced breast cancer: diagnosis and treatment |
| Anastrozole |
08.03.04.01 |
Formulary
|
NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
| Anti-D (Rh0) Immunoglobulin |
14.05.03 |
Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA341 - DVT and PE treatment and secondary prevention |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA245 - Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults |
| Apixaban |
02.08.02 |
Formulary
|
NICE TA275 - Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA 433 Apremilast for treating active psoriatic arthritis |
| Apremilast |
13.05.03 |
Formulary
|
NICE TA419 Apremilast for treating moderate to severe plaque psoriasis |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Aripiprazole |
04.02.01 |
Formulary
|
NICE TA292: Bipolar disorder (children) - aripiprazole |
| Arsenic Trioxide |
08.01.05 |
Formulary
|
NICE TA526 Arsenic trioxide for treating acute promyelocytic leukaemia |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA525 Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA 520 Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab |
08.01.05 |
Restricted Use
|
NICE TA 584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Avelumab |
08.01.05 |
Formulary
|
NICE TA 517 Avelumab for treating metastatic Merkel cell carcinoma |
| Axicabtagene ciloleucel |
08.01.05 |
Formulary
|
NICE TA 559 Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies |
| Axitinib |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for advanced renal cell carcinoma |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA218: azacitidine for myelodysplastic syndromes |
| Azacitidine |
08.01.03 |
Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Baricitinib tablets |
10.01.03 |
Formulary
|
TA 466 Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA 482: Immunosuppressive therapy for kidney transplant in children and young people |
| Basiliximab |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Belimumab |
10.01.03 |
Formulary
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for CLL |
| Bendamustine |
08.01.01 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Benralizumab |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA263: Breast cancer with capecitabine |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA214: Breast Cancer with taxane |
| Bevacizumab |
08.01.05 |
Non Formulary
|
NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab |
| Binimetinib |
08.01.05 |
Formulary
|
NICE TA 562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Bivalirudin |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
| Blinatumomab |
08.02.03 |
Formulary
|
NICE TA 450 Blinatumomab for previously treated Philadelphia-chromosome-negative ALL |
| Blinatumomab |
08.02.03 |
Formulary
|
NICE TA 589 Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Boceprevir |
05.03.03.02 |
Non Formulary
|
NICE TA253: Boceprevir for the treatment of genotype 1 chronic hepatitis C |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA228: 1st line treatment of multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA129: Multiple myeloma - bortezomib |
| Bortezomib |
08.01.05 |
Formulary
|
NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Bosutinib |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum Toxin Type A |
04.07.04.02 |
Formulary
|
NICE TA 260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA 478 Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab vedotin |
08.01.05 |
Formulary
|
NICE TA524 Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brigatinib |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab |
13.05.03 |
Formulary
|
NICE TA 511 Brodalumab for treating moderate to severe plaque psoriasis |
| Cabazitaxel |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA 516 Cabozantinib for treating medullary thyroid cancer |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA542 Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib |
08.01.05 |
Formulary
|
NICE TA 463 Cabozantinib for previously treated advanced renal cell carcinoma |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin for type 2 diabetes |
| Canagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cangrelor |
02.09 |
Formulary
|
NICE TA351: Reducing Artherothrombotic Events |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol |
04.08.01 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Cannabis extract |
10.02.02 |
Formulary
|
NICE NG144 Cannabis-based medicinal products |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Capecitabine |
08.01.03 |
Formulary
|
NICE TA191: Gastric cancer (advanced) - capecitabine |
| Capsaicin 0.025% cream |
10.03.02 |
Formulary
|
NICE CG 177: Osteoarthritis: care and management |
| Capsaicin 0.075% cream |
10.03.02 |
Formulary
|
NICE CG 173: Neuropathic pain in adults: pharmacological management in non-specialist settings |
| Carfilzomib |
08.01.05 |
Formulary
|
NICE TA 457 Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Cemiplimab |
08.01.05 |
Formulary
|
NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA445 Certolizumab pegol and secukinumab for psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab Pegol |
10.01.03 |
Formulary
|
NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA 439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Cetuximab |
08.01.05 |
Formulary
|
NICE TA 473 Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Ciclosporin eye drops |
11.99.99.99 |
Formulary
|
NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet |
09.05.01.02 |
Formulary
|
NICE TA117: Hyperparathyroidism - cinacalcet |
| Cladribine |
08.01.03 |
Formulary
|
NICE TA616: Cladribine for treating relapsing–remitting multiple sclerosis |
| Clopidogrel |
02.09 |
Formulary
|
NICE TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Cobimetinib |
08.02.04 |
Non Formulary
|
NICE TA 414 Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Colistimethate sodium inhaler |
05.01.07 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase clostridium histolyticum |
10.03.01 |
Non Formulary
|
NICE TA 459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA529 Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer |
| Crizotinib |
08.01.05 |
Formulary
|
NICE TA 422 Crizotinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA157 - Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults |
| Dabigatran |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran for Stroke prevention in AF |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA321:Dabrafenib for BRAF V600 +ve melanoma |
| Dabrafenib |
08.01.05 |
Formulary
|
NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Daclatasvir |
05.03.03.02 |
Non Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Daclizumab |
08.02.02 |
Non Formulary
|
NICE TA 441 Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dacomitinib monohydrate |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA 418 Dapagliflozin in triple therapy for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA 510 Daratumumab monotherapy for treating relapsed and refractory multiple myeloma |
| Daratumumab |
08.01.05 |
Formulary
|
NICE TA573 Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Darbepoetin Alfa |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
| Dasabuvir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib |
08.01.05 |
Formulary
|
NICE TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) |
| Degarelix |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA349: Diabetic Macular Oedema |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 460 Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dexamethasone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 229 Dexamethasone intravitreal implant for macular oedema secondary to retinal vein occlusion |
| Diclofenac Gel 1% |
10.03.02 |
Formulary
|
NICE CG 177: Osteoarthritis: care and management |
| Dimethyl fumarate |
08.02.04 |
Non Formulary
|
NICE TA320: Dimethyl fumarate for multiple sclerosis |
| Dimethyl fumarate |
13.05.03 |
Formulary
|
NICE TA 475 Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dipyridamole MR capsules |
02.09 |
Formulary
|
NICE TA210 - Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA101: Prostate cancer (hormone-refractory) - docetaxel |
| Docetaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Docetaxel |
08.01.05 |
Formulary
|
NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Doxorubicin |
08.01.02 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
| Durvalumab |
08.01.05 |
Formulary
|
NICE TA578 Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation |
| Eculizumab |
09.01.03 |
Formulary
|
NICE HST 1 Eculizumab for treating atypical haemolytic uraemic syndrome |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA355 - Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation |
| Edoxaban |
02.08.02 |
Formulary
|
NICE TA354 - Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism |
| Elbasvir/grazoprevir |
05.03.03.02 |
Formulary
|
NICE TA413 Elbasvir–grazoprevir for treating chronic hepatitis C |
| Eltrombopag |
09.01.04 |
Formulary
|
NICE TA293: Eltrombopag for treating chronic ITP |
| Eluxadoline |
01.05 |
Formulary
|
NICE TA 471 Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin for type 2 diabetes |
| Empagliflozin |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Encorafenib |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for prostate cancer |
| Enzalutamide |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Eplerenone tablets |
02.02.03 |
Formulary
|
NICE NG106: Chronic heart failure in adults: diagnosis and management |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin alfa |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy |
| Epoetin beta |
09.01.03 |
Formulary
|
NICE NG8: Chronic kidney disease: managing anaemia |
| Eribulin |
08.01.05 |
Formulary
|
NICE TA 423 Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Eribulin |
08.01.05 |
Non Formulary
|
NICE TA 515 Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA 258 Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Erlotinib |
08.01.05 |
Formulary
|
NICE TA 374 Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA 583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Ertugliflozin |
06.01.02.03 |
Formulary
|
NICE TA 572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept |
10.01.03 |
Formulary
|
NICE TA35: Adult psoriasis |
| Etanercept (biosimilar) injection |
13.05.03 |
Formulary
|
NICE TA 103 Etanercept and efalizumab for the treatment of adults with psoriasis |
| Etanercept (biosimilar) injection |
13.05.03 |
Formulary
|
NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA35: Adult psoriasis |
| Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor |
| Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Etanercept biosimilar |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept injection |
13.05.03 |
Formulary
|
NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Etanercept injection |
13.05.03 |
Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etelcalcetide |
09.05.01.02 |
Formulary
|
NICE TA 448 Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA 449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA 432 Everolimus for advanced renal cell carcinoma after previous treatment |
| Everolimus |
08.01.05 |
Formulary
|
NICE TA 421 Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Evolocumab |
02.12 |
Formulary
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Exemestane |
08.03.04.01 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Exemestane |
08.03.04.01 |
Formulary
|
NICE CG 81 Advanced breast cancer: diagnosis and treatment |
| Exenatide prolonged release |
06.01.02.03 |
Formulary
|
NICE NG 28: Type 2 diabetes in adults: management |
| Ezetimibe |
02.12 |
Formulary
|
NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia |
| Febuxostat |
10.01.04 |
Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Finasteride |
06.04.02 |
Formulary
|
NICE CG97 Lower urinary tract symptoms: quick reference guide |
| Fingolimod |
08.02.04 |
Non Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA119: Leukaemia (lymphocytic) - fludarabine |
| Fludarabine Phosphate |
08.01.03 |
Formulary
|
NICE TA29: Leukaemia (lymphocytic) - fludarabine |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 590 Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone intravitreal implant |
11.04.01 |
Formulary
|
NICE TA 301 diabetic macular oedema |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Fulvestrant |
08.03.04.01 |
Formulary
|
NICE TA579 Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib |
| Gefitinib |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Gemcitabine |
08.01.03 |
Formulary
|
Pancreatic cancer in adults: diagnosis and management |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA116: Breast cancer - gemcitabine |
| Gemcitabine |
08.01.03 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Gemtuzumab ozogamicin |
08.01.05 |
Formulary
|
NICE TA545 Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Glatiramer Acetate |
08.02.04 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glecaprevir/Pibrentasvir |
05.03.03.02 |
Formulary
|
NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| GLIADEL wafer Carmustine 7.6mg |
20 |
Non Formulary
|
NICE TA121: Glioma - carmustine implants and temozolomide |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA220: psoriatic arthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Guselkumab |
13.05.03 |
Formulary
|
NICE TA 521: Guselkumab for treating moderate to severe plaque psoriasis |
| Holoclar® |
11.99.99.99 |
Formulary
|
NICE TA 467 Holoclar for treating limbal stem cell deficiency after eye burns |
| Ibandronic Acid |
06.06.02 |
Restricted Use
|
NICE TA464 - Bisphosphonates for treating osteoporosis |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA 429 Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA 491 Ibrutinib for treating Waldenstrom’s macroglobulinaemia |
| Ibrutinib |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Ibuprofen gel |
10.03.02 |
Formulary
|
NICE CG 177: Osteoarthritis: care and management |
| Idelalisib |
08.01.05 |
Formulary
|
NICE TA359: Chronic lymphocytic leukaemia - Idelalisib |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA 209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA 86 Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA 70 Guidance on the use of imatinib for chronic myeloid leukaemia |
| Imatinib |
08.01.05 |
Formulary
|
NICE TA 326 Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor) |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis |
| Infliximab |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA 187 Infliximab and adalimumab for the treatment of Crohn’s disease |
| Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA 329 Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis |
| Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA163: Ulcerative colitis (acute manifestations) Infliximab |
| Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA187: Crohns disease - infliximab & adalimumab |
| Infliximab (biosimilar) |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis |
| Infliximab (biosimilar) for infusion |
13.05.03 |
Formulary
|
NICE TA 134 Infliximab for the treatment of adults with psoriasis |
| Infliximab (biosimilar) for infusion |
13.05.03 |
Formulary
|
NICE TA 134 Infliximab for the treatment of adults with psoriasis |
| Infliximab for infusion |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for psoriasis |
| Interferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Interferon Alfa - Chronic Hepatitis C |
| Interferon beta-1a |
10.02 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta-1b |
10.02.01 |
Formulary
|
NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab |
08.01.05 |
Formulary
|
NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Irinotecan (pegylated liposomal) |
08.01 |
Non Formulary
|
NICE TA 440 Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
| Irinotecan Hydrochloride |
08.01.05 |
Formulary
|
NICE CG 131 Colorectal cancer: diagnosis and management |
| Ivabradine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Ivabradine |
02.06.03 |
Formulary
|
NICE TA 267 Ivabradine for treating chronic heart failure |
| Ixazomib |
08.02.04 |
Formulary
|
TA 505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
| Ixekizumab injection |
13.05.03 |
Formulary
|
NICE TA 442 Ixekizumab for treating moderate to severe plaque psoriasis |
| Ixekizumab injection |
13.05.03 |
Formulary
|
NICE TA 537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Lamivudine |
05.03.01 |
Formulary
|
NICE CG165: Chronic Hepatitis B |
| Lanadelumab |
03.04.03 |
Formulary
|
TA 606 Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Lapatinib |
08.01.05 |
Restricted Use
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Larotrectinib |
08.01.05 |
Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Ledipasvir and Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 171 Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenalidomide |
08.02.04 |
Formulary
|
NICE TA 587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA 551 Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA 535 Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib |
08.01.05 |
Restricted Use
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Letermovir |
05.03.02.02 |
Formulary
|
NICE TA 591 Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Letrozole |
08.03.04.01 |
Formulary
|
NICE CG 81 Advanced breast cancer: diagnosis and treatment |
| Letrozole |
08.03.04.01 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and treatment |
| Lidocaine medicated plaster 5% |
15.02 |
Restricted Use
|
NICE CG173 - Neuropathic pain in adults: pharmacological management in non-specialist settings |
| Liposomal cytarabine-daunorubicin |
08.01.05 |
Formulary
|
NICE TA552 Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Lorlatinib |
08.01.05 |
Formulary
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Lubiprostone |
01.06.07 |
Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lumacaftor + Ivacaftor |
03.07 |
Non Formulary
|
NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation |
| Lusutrombopag |
09.01.04 |
Formulary
|
NICE TA617 Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Mannitol inhalation |
03.07 |
Non Formulary
|
NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation |
| Mepolizumab |
03.04.02 |
Restricted Use
|
NICE TA 431 Mepolizumab for treating severe refractory eosinophilic asthma |
| Methadone Hydrochloride |
04.10 |
Formulary
|
NICE TA 114 Methadone and Buprenorphine for management of opioid dependence |
| Methylprednisolone |
06.03.02 |
Formulary
|
NICE CG186: Multiple Sclerosis; management in primary and secondary care. |
| Midostaurin |
08.01.05 |
Formulary
|
Midostaurin for untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Non Formulary
|
NICE TA235: Osteosarcoma - mifamurtide: guidance |
| Mirabegron |
07.04.02 |
Formulary
|
NICE TA290: Mirabegron for overactive bladder |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE TA223: Intermittent claudication drugs |
| Naftidrofuryl |
02.06.04 |
Formulary
|
NICE CG147: Lower limb peripheral arterial disease management |
| Nalmefene |
04.10.01 |
Formulary
|
NICE TA 325 Reduction of alcohol consumption in alcohol dependence |
| Naloxegol |
01.06.06 |
Formulary
|
NICE TA 345 Naloxegol for treating opioid‑induced constipation |
| Naltrexone |
04.10.03 |
Formulary
|
NICE TA115: Drug misuse - naltrexone |
| Naltrexone Hydrochloride |
04.10 |
Formulary
|
NICE TA 115 Naltrexone for management of opioid dependence |
| Natalizumab |
08.02.04 |
Non Formulary
|
NICE TA127: Multiple sclerosis - natalizumab |
| Necitumumab |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Neratinib |
08.01.05 |
Formulary
|
NICE TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA 425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nilotinib |
08.01.05 |
Formulary
|
NICE TA 426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nintedanib |
03.11 |
Formulary
|
NICE TA347: Recurrent non-small-cell lung cancer |
| Nintedanib |
03.11 |
Formulary
|
NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib |
08.01.05 |
Formulary
|
NICE TA 347 Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Niraparib |
08.01.05 |
Formulary
|
NICE TA528 Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA417 Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA581 Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA384 Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA400 Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA530 Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA558 Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA462 Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab |
08.02.04 |
Formulary
|
NICE TA484 Nivolumab for previously treated non-squamous non-small-cell lung cancer |
| Nusinersen |
10.02 |
Formulary
|
NICE TA 588 Nusinersen for treating spinal muscular atrophy |
| Obeticholic acid |
01.09.01 |
Formulary
|
NICE TA 443 Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA472 Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA 513 Obinutuzumab for untreated advanced follicular lymphoma |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab with chlorambucil for CLL |
| Obinutuzumab |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Ocrelizumab |
08.02.04 |
Formulary
|
NICE TA 533 Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocrelizumab |
08.02.04 |
Formulary
|
NICE TA 585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ocriplasmin |
11.08.02 |
Formulary
|
NICE TA 297 Ocriplasmin for treating vitreomacular traction |
| Ofatumumab |
08.02.03 |
Formulary
|
NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL |
| Olaparib |
08.02.04 |
Formulary
|
NICE TA620 Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Olaparib |
08.02.04 |
Formulary
|
NICE TA598 Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy |
| Olaratumab |
08.01.05 |
Non Formulary
|
NICE TA 465 Olaratumab with doxorubicin for treating advanced soft tissue sarcoma |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA278: Omalizumab for treating allergic asthma |
| Omalizumab |
03.04.02 |
Formulary
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Ombitasvir/ paritaprevir/ ritonavir |
05.03.03.02 |
Formulary
|
NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Oseltamivir |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Osimertinib |
08.02.04 |
Formulary
|
NICE TA 416 Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer |
| Oxaliplatin |
08.01.05 |
Formulary
|
NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin |
| Pabrinex® |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Pabrinex® |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and management |
| Paclitaxel |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Paclitaxel - Albumin Bound Formulation |
08.01.05 |
Formulary
|
NICE TA 476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Palbociclib |
08.03.04.01 |
Formulary
|
NICE TA619 Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Panitumumab |
08.01.05 |
Formulary
|
NICE TA 439 Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Patiromer |
09.02.01.01 |
Formulary
|
NICE TA623 Patiromer for treating hyperkalaemia |
| Pazopanib |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib in renal cell cancer |
| Pegaspargase |
08.01 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa & ribavirin |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA96: Hepatitis B - peginterferon alfa |
| Peginterferon Alfa |
08.02.04 |
Formulary
|
NICE TA300: Hepatitis C - peginterferon alfa |
| Peginterferon beta 1a |
10.02.01 |
Formulary
|
NICE TA624 Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pegloticase |
20 |
Non Formulary
|
NICE TA291: Pegloticase not recommended for severe chronic gout |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA540 Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA531 Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA557 Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA600 Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA553 Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA519 Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA522Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA357 Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA366 Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab |
08.01.05 |
Formulary
|
NICE TA428 Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance) |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed |
| Pemetrexed |
08.01.03 |
Formulary
|
NICE TA135: Mesothelioma - pemetrexed disodium |
| Pentosan polysulfate sodium capsules |
07.04.03 |
Formulary
|
NICE TA610 Pentosan polysulfate sodium for treating bladder pain syndrome |
| Perampanel |
04.08.01 |
Formulary
|
NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pertuzumab |
08.01.05 |
Formulary
|
NICE TA 424 Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pimecrolimus 1% cream |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Piracetam |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Pirfenidone |
03.11 |
Formulary
|
NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pixantrone |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy |
| Pomalidomide |
08.02.04 |
Formulary
|
NICE TA 427 Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Ponatinib |
08.01.05 |
Formulary
|
NICE TA 451 Ponatinib for treating CML and ALL |
| Prasugrel |
02.09 |
Formulary
|
NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel |
| Prucalopride |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
| Radium-223 dichloride |
08.03.04.02 |
Formulary
|
NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA 160 Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Raloxifene Hydrochloride |
06.04.01.01 |
Formulary
|
NICE TA 161 Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ramucirumab |
08.01.05 |
Non Formulary
|
NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 274 Ranibizumab for treating diabetic macular oedema |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 155 Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 298 Ranibizumab for treating choroidal neovascularisation associated with pathological myopia |
| Ranibizumab |
11.08.02 |
Formulary
|
NICE TA 283 Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion |
| Ranolazine |
02.06.03 |
Formulary
|
NICE CG126: Guidance on Stable Angina (2011) |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA 488 Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Regorafenib |
08.01.05 |
Formulary
|
NICE TA 555 Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib |
08.01.05 |
Non Formulary
|
NICE TA 514 Regorafenib for previously treated advanced hepatocellular carcinoma |
| Reslizumab |
03.04.02 |
Formulary
|
NICE TA 479 Reslizumab for treating severe eosinophilic asthma |
| Retigabine |
04.08.01 |
Non Formulary
|
NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation |
| Ribociclib |
08.03.04.01 |
Restricted Use
|
NICE TA 593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer |
| Rifaximin |
05.01.07 |
Formulary
|
NICE TA 337 Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole |
04.09.03 |
Formulary
|
NICE TA20: Motor neurone disease - riluzole |
| Risankizumab |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Rituximab |
08.02.03 |
Formulary
|
NICE TA 627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor |
| Rituximab |
10.01.03 |
Formulary
|
NICE TA 308 - ANCA vasculitis |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA170 - Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA256 - Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA261 - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA287 - Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA335 - Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome |
| Rivaroxaban |
02.08.02 |
Formulary
|
NICE TA607 Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Roflumilast |
03.03.03 |
Formulary
|
TA 461 Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim |
09.01.04 |
Formulary
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Rucaparib |
08.01.05 |
Formulary
|
NICE TA611 Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Ruxolitinib |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril valsartan |
02.05.05.02 |
Formulary
|
NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources) |
| Sarilumab |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab injection |
10.01.03 |
Formulary
|
NICE TA 445 Certolizumab pegol and secukinumab for psoriatic arthritis after inadequate response to DMARDs |
| Secukinumab injection |
10.01.03 |
Formulary
|
NICE TA 407 Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab injection |
13.05.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab injection |
13.05.03 |
Formulary
|
NICE TA350: Plaque Psoriasis |
| Simeprevir |
05.03.03.02 |
Non Formulary
|
NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C |
| Sipuleucel- T |
20 |
Non Formulary
|
NICE TA322: Sipuleucel-T for prostate cancer |
| Sodium zirconium cyclosilicate |
09.02.01.01 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Sofosbuvir/velpatasvir |
05.03.03.02 |
Formulary
|
NICE TA 430 Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| sofosbuvir/velpatasvir/voxilaprevir |
05.03.03.02 |
Formulary
|
TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) |
| Somatropin |
06.05.01 |
Formulary
|
NICE TA188: Somatropin for growth failure in children |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sorafenib |
08.01.05 |
Formulary
|
NICE TA 474 Sorafenib for treating advanced hepatocellular carcinoma |
| Sotagliflozin |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Stiripentol |
04.08.01 |
Formulary
|
NICE CG137: Epilepsies: diagnosis and management |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA 449 Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA179: Gastrointestinal stromal tumours - sunitinib |
| Sunitinib |
08.01.05 |
Formulary
|
NICE TA169: Renal cell carcinoma - sunitinib |
| Tacrolimus |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Tadalafil |
07.04.05 |
Formulary
|
NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) |
| Talimogene laherparepvac |
08.02.04 |
Formulary
|
NICE TA 410 Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Talimogene laherparepvec |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tamoxifen |
08.03.04.01 |
Formulary
|
NICE CG 81 Advanced breast cancer: diagnosis and treatment |
| Tamoxifen |
08.03.04.01 |
Formulary
|
NICE CG 164 Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer |
| Tamoxifen |
08.03.04.01 |
Formulary
|
NICE NG101: Early and locally advanced breast cancer: diagnosis and treatment |
| Tegafur with Uracil |
08.01.03 |
Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Telaprevir |
05.03.03.02 |
Non Formulary
|
NICE TA252: Telaprevir in hepatitis C |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) |
| Temozolomide |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Tenofovir Disproxil |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Teriflunomide |
08.02.04 |
Non Formulary
|
NICE TA303: Teriflunomide for relapsing remitting MS |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG100: Management of alcohol-related physical complications |
| Thiamine |
09.06.02 |
Formulary
|
NICE CG115: Alcohol dependence - diagnosis, assessment and management |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA236: Ticagrelor for the treatment of acute coronary syndromes |
| Ticagrelor |
02.09 |
Formulary
|
NICE TA 420 Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab |
13.05.03 |
Formulary
|
NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA554 Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years |
| Tisagenlecleucel |
08.01.05 |
Formulary
|
NICE TA 567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies |
| Tivozanib |
08.01.05 |
Formulary
|
NICE TA 512 Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin inhaler |
05.01.04 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA247:Tocilizumab in RA |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis |
| Tocilizumab |
10.01.03 |
Formulary
|
NICE TA 518 Tocilizumab for treating giant cell arteritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA480: tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib |
10.01.03 |
Formulary
|
NICE TA543 Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tolvaptan |
06.05.02 |
Formulary
|
NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan |
| Topotecan |
08.01.05 |
Formulary
|
TA 183 Topotecan for the treatment of recurrent and stage IVB cervical cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA 389 Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Topotecan |
08.01.05 |
Formulary
|
NICE TA184: Lung cancer (small-cell) - topotecan |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA185: Soft tissue sarcoma - trabectedin |
| Trabectedin |
08.01.05 |
Formulary
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Trametinib |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA34: Breast cancer - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab |
| Trastuzumab |
08.01.05 |
Formulary
|
NICE TA 509 Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Trastuzumab emtansine |
08.01.05 |
Formulary
|
NICE TA 458 Trastuzumab emtansine for treating HER2-positive advanced breast cancer |
| Trifluridine-tiparicil tablets |
08.01.03 |
Formulary
|
NICE TA 405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| UrgoStart® |
19.20 |
Formulary
|
NICE MTG 40: UrgoStart for treating diabetic foot ulcers and leg ulcers |
| Ustekinumab |
10.01.03 |
Formulary
|
NICE TA 340 Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
01.05.03 |
Formulary
|
NICE TA 456 Ustekinumab for moderately to severely active Crohn’s disease |
| Ustekinumab injection |
13.05.03 |
Formulary
|
NICE TA 455 Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people |
| Ustekinumab injection |
13.05.03 |
Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Ustekinumab injection |
13.05.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Varenicline |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vedolizumab |
01.05.03 |
Formulary
|
NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vemurafenib |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating malignant melanoma |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA 487 Venetoclax for treating chronic lymphocytic leukaemia |
| Venetoclax |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia |
| Verteporfin |
11.08.02 |
Formulary
|
NICE NG82: Age-related macular degeneration |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vortioxetine |
04.03.03 |
Formulary
|
NICE TA367 - Vortioxetine for treating major depressive episodes |
| Zanamivir inhalation |
05.03.04 |
Formulary
|
NICE TA158: Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza |
| Zanamivir inhalation |
05.03.04 |
Formulary
|
NICE TA168: Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Zolpidem |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
| Zopiclone |
04.01.01 |
Formulary
|
NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia |
